Tag: Deals

  • Ultragenyx Rare Disease Voucher Sales Secure $413M for More Potential Pipeline Building

    Ultragenyx Rare Disease Voucher Sales Secure $413M for More Potential Pipeline Building

    Ultragenyx recently received two separate FDA approvals for gene therapies in the span of a month, each regulatory nod accompanied by a voucher the company could use to speed up the future review of another rare disease drug. In the past week, Ultragenyx has reached separate deals to sell each regulatory fast pass.

    The Novato, California-based biotech announced Wednesday a definitive agreement to sell a voucher for $203 million, following a deal last week to sell a voucher for $210 million. The identities of both voucher buyers were undisclosed and the purchases still need to meet closing conditions. But the deals put Ultragenyx in line for non-dilutive capital that the rare disease specialist can use to bolster its drug pipeline.

    Congress created the voucher program to incentivize drug development in rare diseases. Companies awarded a regulatory approval in a rare pediatric disease can receive one of these vouchers, which cuts the standard review time of 10 months down to six. These vouchers may be sold, and many voucher recipients opt to sell them to big pharmaceutical companies. Demand for these regulatory fast passes has pushed prices higher; most of the vouchers sold this year fetched prices of $200 million or more.

    Ultragenyx received a voucher alongside the late August approval of Gengylcos, a gene therapy for a rare inherited enzyme deficiency called glycogen storage disease type Ia. Another voucher came from the mid-September FDA nod for Fayuvi, a gene therapy for a different rare inherited enzyme deficiency called Sanfilippo syndrome Type A. Each product is the first approved therapy for its respective ultra-rare indication.

    While the Ultragenyx gene therapies carry multi-million-dollar price tags, neither product is expected to become a big revenue driver. Much of the company’s future financial expectations had rested on apazunersen, which was in development for Angelman syndrome, a rare genetic neurological disorder with no FDA-approved therapies. Last month, Ultragenyx reported this antisense oligonucleotide drug failed its Phase 3 test. The company said the disappointing trial outcome would lead to a corporate restructuring and expense reductions.

    The Angelman drug came from an acquisition. Ultragenyx’s two gene therapies also came from business deals. The capital from the voucher sales could be applied toward another deal for a different rare disease therapeutic candidate. While the company made clear its intent to sell both vouchers, it has not said how it will use the proceeds. As of the end of June, Ultragenyx reported its cash position was $436 million. The company is expected to report third quarter 2026 financial results in November.

    Ultragenyx previously received vouchers for rare disease drug approvals in 2017 and 2018. In a prepared statement, Chief Financial Officer Howard Horn noted that the Sanfilippo gene therapy benefited from capital generated by a previous voucher sale, “demonstrating the important role the [priority review voucher] program plays in helping companies develop transformative therapies for rare disease patients.”

    In a Wednesday research note, William Blair analyst Lachlan Hanbury-Brown said that even though Ultragenyx is launching two new gene therapies, the company’s pipeline lacks any clinical catalysts to drive value for the company’s stock in the next year. But the sale of the two vouchers significantly bolsters the biotech’s balance sheet with non-dilutive capital.

    “We look forward to hearing how management plans to strategically deploy this additional capital, as well as details on the company’s expense reductions plans, which we believe will help achieve [generally accepted accounting principles] profitability in 2027,” Hanbury-Brown said.

    Photo: CaptureTheWorld, Getty Images

  • Roche Puts Up $100M to Pursue Promising But Competitive New Target in Obesity

    Roche Puts Up $100M to Pursue Promising But Competitive New Target in Obesity

    For Roche to catch up to Eli Lilly and Novo in metabolic medicines, it needs its drugs to offer differentiation from those rivals. Roche might have just found a way, agreeing to pay $100 million to license a contender that brings a different modality to a new obesity target.

    The drug comes from Shanghai-based Rona Therapeutics. According to deal terms announced Tuesday, Roche gains global rights to the molecule, whose name was not disclosed. It’s the latest in a series of Roche business deals to build up the company’s metabolic drug pipeline.

    Formed in 2021, Rona develops RNA interference (RNAi) drugs, an approach that uses small interfering RNA (siRNA) to degrade messenger RNA, interfering with the translation of a disease-driving protein. This approach is sometimes called “gene silencing.” RNAi drugs first reached patients as treatments for liver disorders, but the field has been working to expand the modality beyond the liver. Roche’s new drug comes from a Rona platform technology that enables extrahepatic drug delivery. Rona also claims its therapies offer the potential to be best in class with longer duration, deep knockdown of target proteins, and improved tolerability.

    The Rona pipeline lists two obesity drug, both in preclinical development for undisclosed targets. The target of Roche’s newly licensed drug is activin receptor-like kinase 7 (ALK7), a protein that is primarily expressed in fat cells. ALK7 plays a role in a signaling pathway that regulates fat storage, the breakdown of stored fats, and the balance of the intake and expenditure of energy.

    Rona points to genetic studies showing that reducing ALK7 activity is associated with favorable results in fat distribution and metabolic measures. Unlike the currently available peptide drugs designed to mimic gut hormones to affect appetite and energy intake, Ronas say ALK7 inhibition acts directly on the biology of fat tissue. This different approach offers the potential for use as a standalone treatment or in combination with established obesity drugs.

    “Obesity represents a significant health challenge that requires differentiated treatment options for patients,” Boris Zaïtra, Roche head of corporate business development, said in a prepared statement. “We are excited to partner with Rona Therapeutics, complementing our robust [cardiovascular, renal & metabolic disease] pipeline and reinforcing our commitment to delivering next-generation metabolic therapies.”

    Roche jumped into obesity drug R&D with the $2.7 billion acquisition of Carmot Therapeutics in 2024. The Carmot drugs address GLP-1 and GIP receptors, the same targets as Lilly and Novo’s obesity drugs. Last year, Roche began a partnership on petrelintide, a Zealand Pharma peptide designed to activate the receptor for amylin, a hormone key to regulating blood sugar and appetite. One goal for petrelintide is reducing fat in a way that does not also lead to muscle loss, a known problem for obesity drugs. Roche added yet another approach to obesity in August, licensing a Hanmi Pharmaceutical peptide designed to activate CRF2 receptors to reduce fat and increase muscle mass.

    With the Rona drug, Roche joins a growing group of companies testing siRNA therapies in obesity. Wave Life Sciences’ siRNA drug WVE-007 goes after a different but related target. It’s designed to silence INHBE, the gene that provides the instructions for activin E, a liver-secreted protein that activates ALK7. Wave has said WVE-007 is intended to stimulate the breakdown of fat while preserving muscle. Late last year, Wave announced preliminary Phase 1 results that it said support once- or twice-yearly dosing. Last month, the company began a Phase 2a study testing WVE-007 in combination with the Lilly obesity drug Zepbound.

    GSK joined the ALK7 chase in May, licensing rights to Suzhou Siran Biotechnology’s SA030, a long-acting siRNA in development for metabolic and vascular diseases. The deal calls for SiranBio to complete the ongoing Phase 1 study. After that, GSK will be responsible for further development of the drug outside of Greater China.

    Arrowhead Pharmaceuticals has two siRNA therapies in development for obesity: the ALK7-targeting drug ARO-ALK7 and the INHBE gene-silencing therapy ARO-INHBE. Both are in Phase 1/2a testing. Meanwhile, RNAi therapies pioneer Alnylam Pharmaceuticals has an INHBE-targeting siRNA drug in preclinical development for obesity.

    Biotech company iBio takes yet another approach with IBIO-610, an antibody designed to block activin E. In July, iBio reported results in monkey tests showing a single dose achieved near complete inhibition of the target protein through eight weeks. These results also showed fat loss and muscle preservation.

    The $100 million that Roche agreed to pay Rona consists of an upfront and near-term milestone payments. Rona could receive up to $1.06 billion more if the drug achieves milestones, plus royalties from sales if it reaches the market.

    Photo: Giuseppe Aresu/Bloomberg, via Getty Images

  • Forbion Bucks VC Fundraising Trends, Reeling In €2.3B for Two New Funds

    Forbion Bucks VC Fundraising Trends, Reeling In €2.3B for Two New Funds

    Forbion, already one of Europe’s largest life sciences venture capital firms, now has more investment firepower with €2.3 billion (about $2.6 billion) raised for two new funds.

    The fundraise is the largest in Forbion’s 20-year history, the Naarden, Netherlands-based firm said Tuesday. It comes in a market generally characterized by a shortage of capital, particularly in Europe.

    This year through the third quarter, VC firms globally have raised $142.1 billion total, according to a new report from Pitchbook. VC fundraising is on pace to top $200 billion for the full year, which would mark a strong rebound from 2025. But the report also shows more money going into fewer funds.

    Furthermore, there’s geographic imbalance in the fundraising. About two thirds of this year’s financial commitments to date are for firms in North America. Pitchbook said that despite this year’s global fundraising already surpassing 2025 figures, Europe is on pace for its lowest fundraising total since 2019, excluding last year.

    The imbalance is also evident in tallies of VC investments. The number of deals and the deal values are up year over year, but that reflects strong activity in North America, the report said. Every other region in the world is on pace for a decline in deal count year over year, which Pitchbook attributes to the lack of liquidity across global markets.

    Forbion said it has already completed the first investments from its two new funds, Forbion Growth Opportunities Fund IV and Forbion Ventures Fund VIII. The firm added that it expects its new capital will support investments in about 30 portfolio companies. In the announcement, Forbion co-founder and Managing Partner Sander Slootweg said the capital enables the firm to invest in “the most exciting biotech companies.”

    “We will continue to focus on building and scaling those companies that develop the most paradigm-shifting treatments, addressing true unmet needs and delivering societal impact,” Slootweg said.

    Forbion’s investments this year to date include participation in the $130 million Series A financing of North Carolina-based migraine drug developer Slate Medicines (now on track to go public in a reverse merger) and the $125 million Series A financing of immunology biotech Coultreon Biopharma, based in Belgium.

    Forbion said its new capital comes from existing investors as well as new ones. Disclosed investors include MN, PGGM, KfW Capital, Kauffman Foundation, and Eli Lilly and Company. With the capital raised for the two new funds, Forbion said it has €7.5 billion (about $8.5 billion) in assets under management spread across 13 funds, making it Europe’s largest dedicated life sciences VC firm.

    Image: mustafaU, via Getty Images

  • Shionogi Adds to Its Rare Disease Strategy With $2B IntraBio Acquisition

    Shionogi Adds to Its Rare Disease Strategy With $2B IntraBio Acquisition

    The growth strategy of Shionogi & Co. is picking up a new piece through the $2 billion acquisition of IntraBio, a biotech company that brings a drug approved in two rare indications along with experience and expertise that complement the Japanese firm’s pipeline of drugs for rare neurological diseases.

    The main IntraBio asset in the deal announced Monday is levacetylleucine, brand name Aqneursa. The FDA initially approved this drug in 2024 as a treatment for the neurological manifestations of Niemann-Pick disease type C, a rare inherited enzyme deficiency. It’s one of just two FDA-approved therapies for this disorder. Last month, the FDA expanded Aqneursa’s label to include ataxia-telangiectasia (A-T), making it the first approved therapy for this rare neurodegenerative disorder.

    Osaka, Japan-based Shionogi established a commercial presence in rare disease through a business deal earlier this year, the $2.5 billion acquisition of global rights to Radicava, an amyotrophic lateral sclerosis drug developed by Tanabe Pharma. Shionogi’s other rare disease drug candidates are also from business deals.

    S-606001, currently in mid-stage clinical development for the rare enzyme deficiency Pompe disease, was licensed from Maze Therapeutics in 2024. Zatolmilast came from Shionogi’s 2020 Tetra Therapeutics acquisition. In May, Shionogi disclosed that this oral small molecule failed two Phase 3 tests in Fragile X syndrome, a genetic disorder that leads to intellectual disability and developmental delays. A separate mid-stage study is still evaluating the molecule in Jordan syndrome, a rare neurodevelopmental disorder.

    Privately held IntraBio was founded in 2015. Its scientific founders hailed from the University of Oxford and the University of Munich, where they discovered and developed small molecules that modulate lysosomal function and intracellular calcium signaling. Initially based in Oxford, U.K., IntraBio relocated to Austin, Texas, in 2024.

    Aqneursa is a modified form of L-leucine, an essential amino acid sourced from food that the body needs for building and repairing muscle and for enabling cells to produce energy. IntraBio’s version of the amino acid is modified in a way intended to help it cross membranes, including the blood-brain barrier. But Aqneursa’s label states that the drug’s mechanism of action for treating Niemann Pick and A-T is unknown. The company has said this drug has potential applications in a range of rare and common neurological disorders. According to Shionogi, Aqneursa generated $67.8 million in revenue in fiscal 2025.

    Shionogi’s largest source of revenue is royalties from HIV drugs marketed by ViiV Healthcare, a company majority owned by GSK. Earlier this year, Shionogi increased its minority ownership stake in ViiV from 10% to 21.7%. Those HIV medicines are part of a broader Shionogi business strategy with a 2030 target date for achieving growth goals. Another goal in this strategy is entering the rare disease business overseas.

    Beyond Aqneursa’s FDA approvals, the drug also received European Commission approval early this year for Niemann Pick disease type C. An additional European regulatory review is ongoing in A-T. In a prepared statement, Shionogi CEO Isao Teshirogi said the IntraBio acquisition shows his company’s commitment to building a global business in rare disease.

    “Bringing Aqneursa to Shionogi after our acquisition of Radicava will deepen our commitment to rare disease communities, expand our capabilities and strengthen our portfolio as we advance future innovation for patients with significant unmet needs,” he said.

    The IntraBio acquisition still needs to clear regulatory reviews. Shionogi said it expects the transaction will close by the end of this year.

    Photo: Soichiro Koriyama/Bloomberg, via Getty Images